Appointment reinforces plans for strategic expansion
Graeme Daniels, PhD, has been appointed as the new Vice President of Sales and Marketing by Sphere Fluidics, a leading provider of microfl uidics-based solutions for single-cell analysis and isolation. He will lead the international sales and marketing strategy, building on the rapid growth and market presence gained from the Company’s rebrand and extensive expansion earlier in 2023, which brought all operations together at science, technology and biopharmaceutical hub Granta Park.
With over 20 years of experience in the life sciences and biotechnology industries, Graeme was formerly Global Sales Leader of Pharma Services at Revvity, Inc, where he successfully developed and implemented sales strategies internationally. He holds a PhD in Developmental Biology from the University of Edinburgh and a BSc in Molecular Genetics in Biotechnology from the University of Sussex.
“We’re very excited to welcome Graeme to the Sphere Fluidics’
team. His extensive experience and leadership in the life sciences industry will be instrumental in driving our international sales and marketing initiatives,” said Dr Frank Craig, CEO, Sphere Fluidics. “As we continue to innovate and expand our product portfolio, his strategic insights will be invaluable in positioning Sphere Fluidics as a leader in single-cell analysis technologies.”
Graeme Daniels added: “Sphere Fluidics is well known across the industry for its commitment to advancing scientifi c research through groundbreaking technologies. I am honoured to take this exciting next step in my career and look forward to working with this highly talented team to accelerate growth and further establish the Company as a key player in the life sciences industry.”
More information online:
ilmt.co/PL/d737 61761pr@reply-direct.com
Graeme Daniels
Funding drives viral challenge agent development forward
to manufacture a human viral challenge agent for evaluating the effectiveness of vaccines in preventing infections. With the support of a $1.87 million (€1.7 million) grant from the Bill & Melinda Gates Foundation, this approach will also accelerate the vaccine development process in support of vaccine development.
The viral challenge agent, an Omicron variant SARS-CoV-2 virus manufactured by Naobios for the foundation, will be used to conduct a Controlled Human Infection Model (CHIM) study. The aim is to support the development of low-cost effective mucosal vaccines to stop respiratory virus transmission, which, with greater breadth, can be deployed to outbreak areas, typically in Low-to-Middle Income Countries (LMICs), to prevent widespread infection.
(Credit: Naobios)
CDMO Naobios, a provider of bioprocess development and GMP production of clinical batches of virus-based products, has plans
The manufacture of Naobios’ viral challenge agent will be followed by stability testing for a period of three years.
“Naobios is excited to receive support from the Bill & Melinda Gates Foundation in its drive to accelerate the development and
commercialisation of novel vaccines and the sustainable manufacture of existing vaccines,” said Eric Le Forestier, General Manager of the French company. “With our experienced team, BSL3 suite and track record in successfully manufacturing several viral strains of challenge agents, we look forward to delivering on this project.”
CHIM studies are increasingly used in several countries such as the US, the UK, the Netherlands and Belgium to investigate all aspects of the course of an infection. In response to this growing need Naobios, situated in Saint Herblain, has invested in extending its current range of services; the company can now offer viral challenge agent manufacturing according to the principles of GMP. It supplies the development and manufacturing of viral challenge agents to global markets.
More information online:
ilmt.co/PL/Qmdx 61875pr@reply-direct.com
Seeking international distributors for laboratory and diagnostic products
With a rich legacy spanning over fi ve decades, Alpha Laboratories has established itself as a leading provider of top-tier laboratory and diagnostic products worldwide. Recognised for its commitment to quality, innovation, and customer satisfaction, the company has become a trusted brand among healthcare, research, and industrial scientists.
Headquartered in the UK, Alpha Laboratories serves its international customers through valued relationships with overseas distributors. The company is actively seeking new alliances with partners in regions such as France, the Middle East, and other markets, including the USA, India, Singapore, Malaysia, and Indonesia.
John Murphy, Alpha Laboratories’ International Business Manager, extends a warm invitation to potential distributors to collaborate with the company. Distributors can anticipate several benefi ts, including access to an extensive range of renowned laboratory products, global reach through an established presence in over
20 countries, comprehensive training and support, exposure to innovative products and technologies, and growth opportunities within a company with a proven track record of success.
Alpha Laboratories values partnership and collaboration, expressing excitement about welcoming new distributors to help the company reach greater heights. For those passionate about science, healthcare, and making a difference, this opportunity provides a chance to join a success story.
To learn more about becoming an international distributor for Alpha Laboratories, interested parties can reach out to the company at
export@alphalabs.co.uk. Together, they can work towards advancing scientifi c excellence globally.
More information online:
ilmt.co/PL/Lo8R 61582pr@reply-direct.com
John Murphy, International Business Manager, Alpha Laboratories.
Beta results prompt early access to AI drug design software
University of Cambridge spin-out DeepMirror, software developers for the discovery of novel therapeutic drugs, has launched an Early Access Programme after a successful closed beta programme during which chemists were invited to test the software over several months. Users were able to tap into AI-driven insights to improve and accelerate molecular design across the drug discovery pipeline through a secure and user-friendly interface which makes AI-powered drug discovery as simple as using a spreadsheet.
The company’s approach, allowing R&D teams to carry out AI-driven research from day one with seamless workfl ow integration, reduces the need for extensive crosstalk between potential partners, and
stakeholders, which can often resulting in long waiting periods with large amounts of resources used by parties involved.
By fast-tracking the drug discovery process, for example in the Hit- to-Lead and Lead Optimisation phases, with the ability to predict relevant properties such as drug binding, (bio-activity) and toxicity, both from user data and from large proprietary curated databases, laboratory results can be used to refi ne predictions and generate novel drug candidates for further experimentation. This will ultimately accelerate the drug discovery process by up to 4 times, (as estimated by the Wellcome Trust and the Boston Consulting Group).
Dr Max Jakobs, Co-Founder and CEO of DeepMirror, commented: “Our
mission is to make AI-powered drug design as simple as browsing the web. After 12 months of development and a successful beta testing programme, we are excited to offi cially launch DeepMirror to early adopters. We are inviting researchers to get in touch to use our secure and user-friendly AI platform for drug design. DeepMirror was already used on active drug discovery programmes and led to the discovery of novel lead series and inspired the synthesis of novel compounds.”
More information online:
ilmt.co/PL/6K44 61876pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
